Ksonef drops Ch. 0.5% 5ml vial-cap.

Description

Composition
Active substance:
1 ml contains: betaxolol hydrochloride equivalent to 5 mg of betaxolol ,.
Excipients:
Benzalkonium chloride 0.1 mg, 2.0 mg of hypromellose, 8.0 mg sodium chloride, sodium hydroxide q.s., disodium edetate 1.0 mg Water for injection to 1.0 ml.
Description:
The clear solution from colorless to pale yellow.
Product form:
0.5% eye drops 5 ml into a plastic dropper-bottle screw cap. Each vial-IV together with instructions for use placed in a cardboard box.
Contraindications
Increased sensitivity to the drug, sinus bradycardia, AV-block II and III degree expressed heart failure, cardiogenic shock, hypotension, children up to 18 years.
Carefully.
thyrotoxicosis, myasthenia gravis, diabetes mellitus, Reynaud’s syndrome, pheochromocytoma, bronchial asthma, chronic obstructive bronchitis.
Dosage
5 mg / ml
Indications
The drug is used to reduce intraocular pressure as monotherapy or in combination with other drugs with open-angle glaucoma, ocular hypertension.
Interaction with other drugs
With the simultaneous application of the drug Ksonef® and beta-blockers for oral administration increases the risk of side effects (both local and systemic) due to the additive effect (so patients receiving this combination of drugs to be under medical supervision).
In applying the drug Ksonef® in combination with drugs that deplete catecholamines (such as reserpine) may experience a decrease in blood pressure and bradycardia.
When concomitant administration of neuromuscular blocking agents and hypoglycemic agents strengthen their actions can be observed.
In a joint application with sympathomimetics – strengthening their vasoconstrictor effect.
Care must be taken when used together Ksonef® drug and psychotropic drugs due to the potential amplification of action.
Overdose
When injected into an excessive amount of eye medication should be rinsed with warm water eyes.
In overdose beta1-adrenoceptor antagonists can be observed decrease in blood pressure, bradycardia, acute heart failure. Treatment is symptomatic.
pharmachologic effect
Pharmacological group:
Antiglaucoma drug – beta-blocker.
Pharmacodynamics:
Antiglaucoma medication. Selective beta1-blocker without intrinsic sympathomimetic activity. Not has a membrane (locally anesthetic) effect.
When applied topically, betaxolol reduces intraocular pressure by reducing the production of intraocular fluid.
The onset of the hypotensive action is observed 30 minutes after instillation, the maximum effect developed after 2 hours. After single instillation influence on ophthalmotonus maintained for 12 hours.
Betaxolol (compared to other beta-blockers) not cause a decrease in blood flow to the optic nerve.
The use of eye drops Ksonef® does not cause miosis, accommodation spasm, night blindness (unlike miotikov).
Pharmacokinetics:
Betaxolol is highly lipophilic, resulting in good penetration through the cornea into the anterior chamber of the eye, C max (1,17 mg / ml) in the anterior chamber is determined 20 minutes after instillation. Penetrates into the systemic circulation. T 1/2 of intraocular fluid about 1 hour. T 1/2 from blood plasma of 16-22 hours. Excretion predominantly through the kidneys.
Pregnancy and breast-feeding
Ksonef® enough experience with the drug during pregnancy and lactation is not.
Use of the drug during pregnancy and lactation (breastfeeding) is possible only when the intended benefits to the mother outweighs the potential risk to the fetus or child.
Conditions of supply of pharmacies
On prescription.
side effects
From a sight organ: often – a short-term discomfort in the eyes after instillation, watery eyes; in some cases – decreased corneal sensitivity, redness of the eye, punctate keratitis, photophobia, anisocoria, photophobia, pruritus, sensation of “dryness” of the eye, allergic reactions.
Systemic side effects are rare:
CNS: dizziness, nausea, drowsiness, insomnia, headache, depression, increased symptoms of myasthenia gravis.
With the cardiovascular system: bradycardia, cardiac conduction and cardiac insufficiency.
The respiratory system: dyspnea, bronchospasm, asthma, respiratory failure.
special instructions
Diabetes.
With care prescribe a drug to patients with diabetes, as beta-blockers may mask the symptoms of acute hypoglycemia.
Thyrotoxicosis.
Precautions drug prescribed to patients with hyperthyroidism, since Beta-blockers may mask the symptoms of hyperthyroidism (eg, tachycardia). In patients with suspected hyperthyroidism should not abruptly cancel beta-blockers, as this may cause an increase in symptoms.
Myasthenia gravis. Keep in mind that beta-blockers can cause symptoms similar to those of myasthenia gravis (diplopia, ptosis, generalized weakness).
Pulmonology.
Precautions should be prescribed beta-blockers in patients with functional disorders of the respiratory system. Despite the fact that clinical studies have shown no effect of betaxolol ophthalmic form on lung function, we can not exclude the possibility of hypersensitivity to the drug.
Surgery. Before planned surgery should gradually cancel beta-blockers for 48 hours prior to general anesthesia, as during general anesthesia may reduce myocardial sensitivity to sympathetic stimulation.
The risk of an anaphylactic reaction. Patients who used beta-blockers may have a history of atopy or anaphylactic reactions. In case of recurrent hypersensitivity reactions such patients may not be sensitive to the usual doses of epinephrine (adrenaline) required for the relief of anaphylaxis.
The drug should be used with caution in patients with Raynaud’s syndrome or pheochromocytoma.
When instilled into the eyes of beta-blockers may be absorbed into the systemic circulation. This may mark the same side effects as when administered systemically. Cases of severe respiratory and cardiovascular disorders, including bronchospasm fatal in patients with bronchial asthma and death from heart failure.
Ksonef® has minimal effect on blood pressure and heart rate. However, caution should be exercised when administering the drug to patients with AV-I blockade degree and mild to moderate congestive heart failure. Treatment with Ksonef® should be discontinued immediately at the first signs of decompensation of the cardiovascular system.
Ksonef® preservative comprises benzalkonium chloride which may be deposited on the soft contact lenses and have a toxic effect on the eye tissue. Therefore, patients wearing contact lenses, it is necessary to remove them before applying droplets and set back no earlier than 20 minutes after instillation.
Effects on ability to drive vehicles and management mechanisms.
If after applying the drops in patients temporarily reduced the clarity of vision to its recovery is not recommended to drive and engage in activities that require attention and reaction.
Storage conditions
The drug should be stored at temperatures not above 30 ° C, protected from light. Do not freeze.
Keep out of the reach of children.
Dosing and Administration
The drug instilled in the conjunctival sac of 1-2 drops 2 times per day.
In some patients, stabilization of intraocular pressure occurs within a few weeks, so it is recommended to monitor the intraocular pressure within the first month of treatment.
In case of insufficient clinical monotherapy prescribe additional therapy.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist